CTIS2022-502700-78-00招募中1 期
I4V-MC-JAIO: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Baricitinib in Children from 6 Years to less than 18 Years of Age with Alopecia Areata - I4V-MC-JAIO
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 603
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 17（—）
- 性别
- All
入选标准
- •Have severe areata alopecia (AA) for at least 1 year, Current AA episode of at least 6 months’ duration with hair loss encompassing =50% of the scalp, Current episode of severe to very severe alopecia areata of less than 8 years. - Participants who have severe AA for = 8 years may be enrolled if episodes of regrowth, spontaneous or under treatment, have been observed on the affected areas over the past 8 years
排除标准
- •Participants must not have primarily diffuse” type of alopecia areata, Participants must not be currently experiencing other forms of alopecia or any other health problem that would make it difficult to see how the study drug is working on alopecia areata, Participants must not have topical applied to scalp within 4 weeks of randomization
研究者
相似试验
进行中（未招募）
1 期
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate CancerProstate CancerCTIS2023-506777-36-00Eli Lilly & Co.304
招募中
1 期
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-OUTCOMES)CTIS2023-508630-34-00Eli Lilly & Co.10,000
进行中（未招募）
1 期
A Study of Tirzepatide (LY3298176) on the Reduction of Morbidity and Mortality in Adults With Obesity (SURMOUNT- MMO)CTIS2022-501744-15-00Eli Lilly & Co.15,000
进行中（未招募）
1 期
A study in people with Cystic Fibrosis ( a rare hereditary lung disease) to assess the efficacy and safety of a combination of two experimental drugsMedDRA version: 18.1Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersCystic FibrosisEUCTR2014-004838-25-BEVertex Pharmaceuticals Incorporated200
进行中（未招募）
1 期
A study in people with Cystic Fibrosis ( a rare hereditary lung disease) to assess the efficacy and safety of a combination of two experimental drugsMedDRA version: 20.0Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersCystic FibrosisEUCTR2014-004838-25-DEVertex Pharmaceuticals Incorporated156